NASDAQ : LTRN
Lantern Pharma Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.6608 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.77M | 6.46M | 6.09M | 5.98M | 5.83M | 5.02M |
| Research & Development | 8.70M | 11.51M | 16.13M | 11.89M | 8.60M | 6.57M |
| Operating Expenses | 15.47M | 17.98M | 22.22M | 17.88M | 14.43M | 11.59M |
| Operating Income | -15.47M | -17.98M | -22.22M | -17.88M | -14.43M | -11.59M |
| Interest & Investment Income | 245.63K | 437.93K | 742.36K | 765.39K | 204.35K | 67.93K |
| Other Non Operating Income (Expenses) | -3.38M | 380.15K | 537.25K | 1.15M | -31.55K | 50.55K |
| EBT Excluding Unusual Items | -18.60M | -17.16M | -20.94M | -15.96M | -14.26M | -11.47M |
| Gain (Loss) on Sale of Investments | -55.34K | 40.97K | 155.62K | |||
| Other Unusual Items | -890.00K | |||||
| Pretax Income | -18.65M | -17.12M | -20.78M | -15.96M | -14.26M | -12.36M |
| Net Income | -18.65M | -17.12M | -20.78M | -15.96M | -14.26M | -12.36M |
| Net Income to Common | -18.65M | -17.12M | -20.78M | -15.96M | -14.26M | -12.36M |
| Shares Outstanding (Basic) | 11.43M | 10.90M | 10.76M | 10.84M | 10.85M | 10.90M |
| Shares Outstanding (Diluted) | 11.43M | 10.90M | 10.76M | 10.84M | 10.85M | 10.90M |
| EPS (Basic) | -1.63 | -1.57 | -1.93 | -1.47 | -1.31 | -1.13 |
| EPS (Diluted) | -1.63 | -1.57 | -1.93 | -1.47 | -1.31 | -1.13 |
| Free Cash Flow | -14.08M | -15.68M | -17.83M | -14.37M | -12.80M | -10.61M |
| Free Cash Flow Per Share | -1.23 | -1.44 | -1.66 | -1.32 | -1.18 | -0.97 |
| EBITDA | -15.45M | -17.96M | -22.20M | -17.86M | -14.42M | -11.58M |
| D&A For EBITDA | 15.81K | 17.28K | 17.28K | 14.62K | 10.08K | 6.76K |
| EBIT | -15.47M | -17.98M | -22.22M | -17.88M | -14.43M | -11.59M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.66M | 4.42M | 7.51M | 21.94M | 37.20M | 51.52M |
| Short-Term Investments | 701.09K | 5.70M | 16.50M | 19.36M | 17.99M | 19.20M |
| Cash & Short-Term Investments | 7.36M | 10.12M | 24.01M | 41.30M | 55.20M | 70.73M |
| Other Receivables | 34.00K | 30.00K | 97.00K | 859.65K | 592.00K | 181.00K |
| Receivables | 34.00K | 30.00K | 97.00K | 859.65K | 592.00K | 181.00K |
| Prepaid Expenses | 579.00K | 653.95K | 1.14M | 1.18M | 760.00K | 1.03M |
| Restricted Cash | 541.18K | |||||
| Other Current Assets | 484.66K | 1.63M | 777.95K | |||
| Total Current Assets | 8.46M | 10.80M | 25.25M | 43.34M | 58.72M | 72.72M |
| Property, Plant & Equipment | 62.51K | 107.47K | 287.43K | 280.42K | 95.69K | 216.19K |
| Long-Term Deferred Charges | 54.83K | 88.43K | ||||
| Other Long-Term Assets | 26.09K | 36.74K | 36.74K | 25.87K | 17.89K | 1.02M |
| Total Assets | 8.60M | 11.04M | 25.57M | 43.65M | 58.84M | 73.95M |
| Accounts Payable | 3.35M | 3.06M | 2.42M | 942.21K | 932.41K | 681.11K |
| Current Portion of Leases | 39.72K | 78.54K | 190.81K | 172.97K | 52.89K | 152.06K |
| Other Current Liabilities | 935.00K | 1.36M | 1.73M | 1.56M | 1.81M | 1.49M |
| Total Current Liabilities | 4.32M | 4.50M | 4.33M | 2.68M | 2.80M | 2.33M |
| Long-Term Leases | 52.84K | 61.50K | 52.89K | |||
| Total Liabilities | 11.82M | 4.50M | 4.38M | 2.74M | 2.80M | 2.38M |
| Common Stock | 1.28K | 1.12K | 1.08K | 1.07K | 1.09K | 1.11K |
| Additional Paid-In Capital | 100.37M | 99.65M | 97.06M | 96.26M | 95.69M | 96.69M |
| Retained Earnings | -103.55M | -93.15M | -76.03M | -55.24M | -39.28M | -25.02M |
| Comprehensive Income & Other | -39.76K | 25.43K | 153.99K | -107.46K | -371.39K | -92.69K |
| Total Common Equity | -3.22M | 6.53M | 21.19M | 40.91M | 56.04M | 71.57M |
| Shareholders' Equity | -3.22M | 6.53M | 21.19M | 40.91M | 56.04M | 71.57M |
| Total Liabilities & Equity | 8.60M | 11.04M | 25.57M | 43.65M | 58.84M | 73.95M |
| Total Debt | 39.72K | 78.54K | 243.66K | 234.47K | 52.89K | 204.95K |
| Net Cash (Debt) | 7.32M | 10.04M | 23.77M | 41.07M | 55.14M | 70.52M |
| Net Cash Per Share | 0.64 | 0.92 | 2.21 | 3.79 | 5.08 | 6.47 |
| Filing Date Shares Outstanding | 12.78M | 11.25M | 10.78M | 10.74M | 10.86M | 10.78M |
| Total Common Shares Outstanding | 12.76M | 11.25M | 10.78M | 10.72M | 10.86M | 11.09M |
| Working Capital | 4.14M | 6.30M | 20.92M | 40.66M | 55.92M | 70.39M |
| Book Value Per Share | -0.25 | 0.58 | 1.96 | 3.82 | 5.16 | 6.45 |
| Tangible Book Value | -3.22M | 6.53M | 21.19M | 40.91M | 56.04M | 71.57M |
| Tangible Book Value Per Share | -0.25 | 0.58 | 1.96 | 3.82 | 5.16 | 6.45 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -18.65M | -17.12M | -20.78M | -15.96M | -14.26M | -12.36M |
| Depreciation & Amortization | 243.06K | 207.18K | 190.49K | 174.84K | 148.34K | 95.29K |
| Loss (Gain) From Sale of Investments | -28.15K | -259.81K | -403.26K | -176.90K | 703.29K | 221.06K |
| Stock-Based Compensation | 1.42M | 1.02M | 732.89K | 1.07M | 1.19M | 961.54K |
| Other Operating Activities | 3.40M | -157.97K | 219.73K | 11.50K | 64.94K | -106.37K |
| Change in Accounts Payable | -582.97K | 271.81K | 1.64M | -236.18K | 580.36K | 1.62M |
| Change in Other Net Operating Assets | 83.33K | 363.47K | 591.72K | 774.21K | -1.19M | -1.02M |
| Operating Cash Flow | -14.08M | -15.68M | -17.81M | -14.35M | -12.77M | -10.59M |
| Capital Expenditures | -556.00 | -1.72K | -12.60K | -18.73K | -27.84K | -15.50K |
| Investment in Securities | 9.17M | 11.06M | 3.38M | -911.48K | 207.11K | -19.52M |
| Investing Cash Flow | 9.17M | 11.06M | 3.37M | -930.21K | 179.27K | -19.53M |
| Issuance of Common Stock | 5.63M | 1.64M | 66.71K | 299.79K | 69.14M | |
| Repurchase of Common Stock | -500.00K | -2.48M | -939.67K | |||
| Other Financing Activities | -139.75K | -139.75K | -4.78M | |||
| Financing Cash Flow | 5.49M | 1.50M | 66.71K | -500.00K | -2.18M | 63.42M |
| Foreign Exchange Rate Adjustments | 19.62K | 33.43K | -49.55K | -28.46K | -10.61K | 1.07K |
| Net Cash Flow | 598.76K | -3.09M | -14.43M | -15.81M | -14.78M | 33.30M |
| Free Cash Flow | -14.08M | -15.68M | -17.83M | -14.37M | -12.80M | -10.61M |
| Free Cash Flow Per Share | -1.23 | -1.44 | -1.66 | -1.32 | -1.18 | -0.97 |
| Levered Free Cash Flow | -8.24M | -9.18M | -10.54M | -8.70M | -8.68M | -5.56M |
| Unlevered Free Cash Flow | -8.27M | -9.18M | -10.54M | -8.70M | -8.68M | -5.56M |
| Change in Working Capital | -499.64K | 635.28K | 2.23M | 538.02K | -611.86K | 599.96K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 8.18M | 33.89M | 34.40M | 46.52M | 65.58M | 89.28M |
| Enterprise Value | 860.31K | 21.62M | 6.64M | 1.87M | 7.84M | 15.69M |
| Last Close Price | 0.64 | 3.03 | 3.19 | 4.28 | 6.04 | 7.98 |
| PB Ratio | 5.19 | 1.62 | 1.14 | 1.17 | 1.25 | |
| P/TBV Ratio | 5.19 | 1.62 | 1.14 | 1.17 | 1.25 | |
| Debt / Equity Ratio | -0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Net Debt / Equity Ratio | 2.28 | -1.54 | -1.12 | -1.00 | -0.98 | -0.98 |
| Net Debt / EBITDA Ratio | 0.47 | 0.56 | 1.07 | 2.30 | 3.82 | 6.09 |
| Net Debt / FCF Ratio | 0.52 | 0.64 | 1.33 | 2.86 | 4.31 | 6.65 |
| Quick Ratio | 1.71 | 2.25 | 5.57 | 15.74 | 19.94 | 30.48 |
| Current Ratio | 1.96 | 2.40 | 5.83 | 16.18 | 20.98 | 31.26 |
| Return on Equity (ROE) | -400.92% | -123.51% | -66.93% | -32.93% | -22.35% | -27.09% |
| Return on Assets (ROA) | -74.29% | -61.39% | -40.12% | -21.80% | -13.59% | -15.36% |
| Return on Capital Employed (ROCE) | -361.40% | -275.10% | -104.60% | -43.60% | -25.80% | -16.20% |
| Earnings Yield | -255.07% | -50.52% | -60.41% | -34.31% | -21.75% | -13.85% |
| FCF Yield | -172.07% | -46.27% | -51.81% | -30.88% | -19.51% | -11.88% |
| Buyback Yield / Dilution | -6.00% | -1.26% | 0.74% | 0.08% | 0.50% | -153.31% |